Abstract
Secretory leukocyte protease inhibitor (SLPI) is a naturally occurring protein of human airways that exhibits broad spectrum inhibitory activity against mast cell and leukocyte serine proteases implicated in asthma pathology. To assess the potential therapeutic utility of SLPI in this disorder, its effects on antigen-induced pulmonary responses were evaluated. In Ascaris-sensitized sheep, SLPI (3 mg) administered by aerosol daily for 4 days, with the final dose 0.5 h before antigen challenge, reduced the areas under the curve for early- and late-phase bronchoconstriction (73 and 95%, respectively;p < .05 versus control responses). SLPI also inhibited the development of airway hyperresponsiveness to carbachol (84%, p < .05 versus control response) measured 24 h after antigen challenge. In ovalbumin-sensitized guinea pigs, intratracheal administration of SLPI daily for 3 days, with the final dose 1 h before antigen challenge, inhibited the development of airway hyperresponsiveness to histamine with an ED50 of <0.05 mg/kg. Prolonged pharmacodynamic activity of SLPI was observed in both species. In a murine model of atopic asthma, SLPI inhibited leukocyte influx into the airways after chronic allergen challenge. SLPI administered to sheep by the predosing protocol described above also prevented the antigen-induced decrease of tracheal mucus velocity (p < .05). In addition, a single aerosol administration of SLPI (30 mg) to sheep 1 h after antigen challenge inhibited the subsequent late-phase bronchoconstriction and development of hyperresponsiveness and reversed the stimulated decrease in tracheal mucus velocity. These results suggest that SLPI may provide therapeutic intervention against the pathophysiology of asthma and its underlying pathology.
Footnotes
-
Send reprint requests to: Clifford D. Wright, Ph.D., Department of Pharmacology, Amgen, Inc., 1 Amgen Center Drive, Mailstop 15-2-a, Thousand Oaks, CA 91320. E-mail:cwright{at}amgen.com
-
↵1 Support for this research was provided by Amgen, Inc., Thousand Oaks, CA. This work was presented in abstract form at the 1997 Annual Meeting of the American Thoracic Society.
- Abbreviations:
- SLPI
- secretory leukocyte protease inhibitor
- pNA
- p-nitroanilide
- BSA
- bovine serum albumin
- RL
- mean pulmonary flow resistance
- Vtg
- thoracic gas volume
- SRL
- specific lung resistance
- PBS
- phosphate-buffered saline
- Penh
- pause enhanced
- Te, total expiratory time
- RT,relaxation time
- PEF, peak expiratory flow
- PIF, peak inspiratory flow
- i.t.
- intratracheal
- Received October 19, 1998.
- Accepted January 5, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|